XML 14 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended
Oct. 03, 2018
USD ($)
Target
Obligation
Dec. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from the issuance of common stock   $ 250,500,000 $ 250,476,739 $ 60,521,729  
Revenues     29,454,579 34,657,896  
Deferred revenue   54,034,129 54,034,129   $ 77,769,629
Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Initial transaction price $ 252,600,000        
JJDC | Common Stock Purchase Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from the issuance of common stock 75,000,000        
JJDC | JNJ-3989 (ARO-HBV) Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenues       34,700,000  
Janssen and JJDC | Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cash received as due under collaboration agreement $ 175,000,000        
Janssen          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Number of distinct performance obligations | Obligation 1        
Janssen | Common Stock Purchase Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Agreement date Oct. 03, 2018        
Janssen | License Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Agreement date Oct. 03, 2018        
Janssen | License Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Development, regulatory and sales milestones payments $ 1,600,000,000        
Janssen | Research Collaboration and Option Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Agreement date Oct. 03, 2018        
Janssen | Collaboration Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Number of additional targets for development, regulatory and sales milestone payments | Target 3        
Janssen | Collaboration Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Development, regulatory and sales milestones payments $ 1,900,000,000        
Janssen | JNJ-3989 (ARO-HBV) Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payment $ 25,000,000 25,000,000 25,000,000    
Revenues     28,800,000    
Contract assets   0 0    
Deferred revenue   54,000,000.0 54,000,000.0    
Janssen | ARO-JNJ1          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenues     700,000 $ 0  
Contract assets   1,300,000 1,300,000    
Contract liabilities   $ 0 $ 0